From: Cancer-associated adipocytes: key players in breast cancer progression
Agent | Target | In vitro effect | Preclinical and clinical effects | References |
---|---|---|---|---|
Cenicriviroc | CCR2 | Inhibitor of CCR2 | Inhibition of monocyte recruitment, Prevent virus from entering into a human cell | |
Maraviroc | CCR5 | Inhibitor of CCR5 | Blockade the HIV from entering macrophages and T cells | [139] |
Tocilizumab | IL-6R | Monoclonal antibody against IL-6R | Hindering IL-6 from exerting its pro-inflammatory effects. | [140] |
Canakinumab | IL-1β | Monoclonal antibody against IL-1β | Treatment of cryopyrin-associated periodic syndromes | [141] |
Infliximab | TNF-α | Monoclonal antibody against TNF-α | Treatment of autoimmune diseases | |
Bevacizumab (Avastin) | VEGF | Monoclonal antibody against VEGF-A | Angiogenesis inhibitor | [145] |
AZD3695 | MCT1 | MCT1 inhibition | Reduce tumor growth, Increase intra-tumor lactate | [146] |
Nivolumab | PD-1 | Monoclonal antibody against PD-1 | Checkpoint inhibitor | [147] |
Durvalumab | PD-L1 | Monoclonal antibody against PD-L1 | Blocking the interaction of PD-L1 with the PD-1 and CD80 (B7.1) molecules. | [148] |
Avelumab | PD-L1 | Monoclonal antibody against PD-L1 | Blocking the interaction of PD-L1 binding to PD-1 | [149] |